Enthusiastic and results-driven professional with a strong desire to contribute to team success through hard work, attention to detail, and excellent organizational skills. Passionate about being part of an organization that values mutual growth, where continuous learning and exploring talents are encouraged to help reach full potential. Committed to delivering high-quality results, thrives in collaborative environments, and enjoys working with diverse teams to achieve collective goals. Currently seeking a dynamic environment that offers ample opportunities for personal and professional development.
Senior Safety Science Specialist at Fortrea (Labcorp ), Bangalore- MAR 2023 to till date.
Safety Science Specialist at Labcorp (Covance), Bangalore- MAR 2021 to MAR 2023
Operations Specialist I at IQVIA, Bangalore – DEC 2017 to MAR 2021
Experience Summary:
• 6. 11 years of experience in pharmacovigilance and drug safety.
• Experience in coding of events, medical history by using MEDRA dictionaries.
• End to End Serious and Non-Serious Case Handling/Quality Review of legal, Spontaneous, Solicited and Clinical Trial cases.
• End to End Pharmacovigilance Experience in book in, triaging, Data Entry, Medical coding, Quality Review, Safety narrative, Finalization, Regulatory report generation as per timelines.
• To perform Pharmacovigilance activities per project requirement including but not limited to, collecting and tracking incoming Adverse Events(AE)/endpoint information; determining initial/update status of incoming events; database entry; coding AE and Products, writing narratives.
Therapeutic Experience
· Cardio Metabolic: Metabolic and Cardiovascular Risk - Hypertension (Phase IV)
· Immune Mediated Inflammatory Disease (IMID): Dermatologic - Psoriasis (Phase IV), Inflammatory Bowel - Crohn’s disease (Phase IV), Ulcerative colitis (Phase IV), Systemic IMID - Psoriatic arthritis (Phase IV), Ankylosing spondylitis (Phase IV)
· Oncology: Hematologic Malignancies – Multiple Myeloma (Phase IV)
· Hematology: Lymphoma – Follicular lymphoma (Phase II)
· Oncology: Lung Cancer – NSCLC (Non-Small Cell Lung Cancer Phase II
· Hematology: Plasma Cell Dyscrasias – Multiple Myeloma Phase II
· Hematology: Lymphoma – Diffuse large B cell lymphoma (DLBCL) Phase II and Phase IIIVaccine (Covid 19 Vaccine)
Diploma In Clinical Research, NIDA Certification